Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Effects of Cardiovascular Risk Screening in Pharmacies: A Randomized Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02223793
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:43.475156+00:00
Published At
2019-10-03T00:00:00+00:00
Record Updated At
2020-05-06
Results Posted At
2019-10-03
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Cardiovascular Diseases", "Hypercholesterolemia", "Dyslipidemia", "Hypertensive Disease", "Diabetes Mellitus, Type 2"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-05-06"
protocolSection.identificationModule.nctId
"NCT02223793"
protocolSection.identificationModule.officialTitle
"Effects of Cardiovascular Risk Screening in Pharmacies: A Randomized Study"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["NA"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2019-10-03"

Study condition terms

  • Cardiovascular Diseases (protocolSection.conditionsModule.conditions)
  • Hypercholesterolemia (protocolSection.conditionsModule.conditions)
  • Dyslipidemia (protocolSection.conditionsModule.conditions)
  • Hypertensive Disease (protocolSection.conditionsModule.conditions)
  • Diabetes Mellitus, Type 2 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.